Marketing System and Efficiency of Indian Major Carps in India

The Kolleru Lake area (KLA) in Andhra Pradesh being a predominant centre for carp culture is known as the ‘Carp Pocket of India’. This paper has described the highly efficient fish marketing system prevalent in the KLA and has compared it with the marketing of Indian Major Carps (IMC) in other major aquaculture states like West Bengal and Orissa and marine states like Maharashtra and Tamil Nadu. The marketing channels, market intermediaries, price spread and marketing efficiency have been presented. A comparison of the marketing channels at several fish markets has revealed that the price spread for IMC from Kolleru is highest at the Mumbai market and lowest at the Coimbatore market. Consequently, fishermen’s share in consumer price has been found highest for Coimbatore at 61.54 per cent and lowest for Mumbai at 47.06 per cent. Similarly, the marketing efficiency was the highest for Coimbatore at 2.60 and lowest for Mumbai at 1.89. Retail price for KLA carps has been found lower than locally cultured carps at various areas, reflecting the efficiency of the marketing channel in providing cheap fish transported over large distances and through a large number of intermediaries. The reasons for the efficient IMC marketing system at KLA have been discussed and the study has recommended the development of efficient fish marketing system in other parts of the country.Agricultural and Food Policy,

Micro Expression Spotting through Appearance Based Descriptor and Distance Analysis

Micro-Expressions (MEs) are a typical kind of expressions which are subtle and short lived in nature and reveal the hidden emotion of human beings. Due to processing an entire video, the MEs recognition constitutes huge computational burden and also consumes more time. Hence, MEs spotting is required which locates the exact frames at which the movement of ME persists. Spotting is regarded as a primary step for MEs recognition. This paper proposes a new method for ME spotting which comprises three stages; pre-processing, feature extraction and discrimination. Pre-processing aligns the facial region in every frame based on three landmark points derived from three landmark regions. To do alignment, an in-plane rotation matrix is used which rotates the non-aligned coordinates into aligned coordinates. For feature extraction, two texture based descriptors are deployed; they are Local Binary Pattern (LBP) and Local Mean Binary Pattern (LMBP). Finally at discrimination stage, Feature Difference Analysis is employed through Chi-Squared Distance (CSD) and the distance of each frame is compared with a threshold to spot there frames namely Onset, Apex and Offset. Simulation done over a Standard CASME dataset and performance is verified through Feature Difference and F1-Score. The obtained results prove that the proposed method is superior than the state-of-the-art methods

ENDO-PERIO LESION: A CASE REPORT

The pulp and periodontium have embryonic, anatomic and functional interrelationships. The simultaneous existence of pulpal problems and inflammatory periodontal disease can complicate diagnosis and treatment planning. This case report evaluates the efficacy of G-Bone graft in the management of vertical bone loss associated with an endo-perio lesion in a left mandibular first molar and second molar. A 40 year-old male patient with an endo-perio lesion in the left mandibular first and second molars was initially treated with endodontic therapy. Following the endodontic treatment, the defect was treated using G-Bone graft. At the end of 6 months, there was a gain in the clinical attachment level and reduction in probing depth. Radiographic evidence showed that there was a significant bony fill. Keywords: Endo - perio lesion; Vertical bone loss; G - Bone graft

PHYTOCHEMICAL AND PHARMACOLOGICAL EVALUATION OF GLORIOSA SUPERBA

Gloriosa superba Linn. is an important medicinal plant ( Liliaceae). It is a semi-woody herbaceous branched climber reaching approximately 5 meters height, with brilliant wavy-edged yellow and red flowers 1. Being native form Indian especially Southern India it is known as glory lily and climbing lily- in English. In the world market glory lily considered as rich source of colchicines and gloriosine 4. The flower has analgesic, anti-inflammatory potential, antimicrobial, larvicidal potential, antipoxviral potential, antithrombotic potential, antitumor potential, enzyme inhibition potential, and also used in treatment of snake bite, Skin disease, respiratory disorders 5, 6, 7, 8, 9. Medicinal plants have been used as sources of medicine in virtually all cultures 10, 11. In recent years, there has been a gradual revival of interest in the use of medicinal plants in developing countries because herbal medicines have been reported safe and without any adverse side effect especially when compared with synthetic drugs. Thus a search for new drugs with better and cheaper substitutes from plant origin is a natural choice. The medicinal values of these plants lie in some chemical substances that produce a definite physiological action on human body 12. Different parts of G. superba have wide variety of uses especially in traditional system of medicine. The tuber is used for the treatment of bruises and sprains, colic, chronic ulcers, haemorrhoids, cancer, impotence, nocturnal seminal emission, and leprosy and also for including labour pains and abortions 13. Gloriosa superba also used in wounds, skin related problems, Fever, Inflammation, piles, blood disorders, Uterine contractions, General body toner, Poisoning 14, 15. Roots are acrid, anthelmintic, antipyretic, bitter, digestive, expectorant, highly poisonous and promoting expulsion of the placenta. Root paste is effective against paralysis, rheumatism, snake bite and insect bites 16. This plant has gained the importance in medicine in recent years for the production of colchicine in large scale 17. The aim of this study was to identify and determine the phytochemicals present in G. superba leaves, flowers, seeds and tubers. The main MeOH & dichloromethane extract were isolated and evaluated for anticancer activity.Keywords: Gloriosa superba, MeOH extract, CDCl2 Extract,  anticancer activit

Construction of Knowledge Test to Measure the Knowledge on Recommended Groundnut Production Practices

The non-availability of a standardized scale to measure the farmers’ knowledge level influenced the researchers to construct a test for measuring the knowledge on recommended groundnut production package of practices. Pertinent items were collected covering all aspects from the crop production guide developed by the Department of Agriculture, Govt. of Tamil Nadu & Tamil Nadu Agricultural University. After getting jury opinion on the items, test index of item difficulty, index of item discrimination and point biserial correlation for the items were worked out. All these were taken in to account to arrive at the final scale. While administrating the knowledge test a respondent was given one mark for each correct answer and zero for wrong answer. Eleven (11) items were finally selected from a total of fifty five (55) items

HIV infection and drugs of abuse: role of acute phase proteins

Background HIV infection and drugs of abuse such as methamphetamine (METH), cocaine, and alcohol use have been identified as risk factors for triggering inflammation. Acute phase proteins such as C-reactive protein (CRP) and serum amyloid A (SAA) are the biomarkers of inflammation. Hence, the interactive effect of drugs of abuse with acute phase proteins in HIV-positive subjects was investigated. Methods Plasma samples were utilized from 75 subjects with METH use, cocaine use, alcohol use, and HIV-positive alone and HIV-positive METH, cocaine, and alcohol users, and age-matched control subjects. The plasma CRP and SAA levels were measured by ELISA and western blot respectively and the CD4 counts were also measured. Results Observed results indicated that the CRP and SAA levels in HIV-positive subjects who are METH, cocaine and alcohol users were significantly higher when compared with either drugs of abuse or HIV-positive alone. The CD4 counts were also dramatically reduced in HIV-positive with drugs of abuse subjects compared with only HIV-positive subjects. Conclusions These results suggest that, in HIV-positive subjects, drugs of abuse increase the levels of CRP and SAA, which may impact on the HIV infection and disease progression

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions